卡瑞利珠单抗+白蛋白紫杉醇+奈达铂/顺铂治疗老年晚期食管癌的临床疗效观察  

Clinical observation of carelizumab combined with albumin paclitaxel and nedaplatin/cisplatin in treatment of elderly patients with advanced esophageal cancer

作　　者：季德林 冯克海[2] 谢韬 De-lin Ji;Ke-hai Feng;Tao Xie(Department of Interventional Oncology,West District of Anhui provincial Hospital,Hefei,Anhui 230031,China;Department of Medical Oncology,West District of Anhui provincial Hospital,Hefei,Anhui 230031,China)

机构地区：[1]安徽省立医院西区肿瘤介入科,安徽合肥230031 [2]安徽省立医院西区肿瘤内科,安徽合肥230031

出　　处：《中国现代医学杂志》2022年第23期6-10,共5页China Journal of Modern Medicine

基　　金：安徽省自然科学基金(No:1808085MH266)。

摘　　要：目的探讨卡瑞利珠单抗+白蛋白紫杉醇+奈达铂/顺铂治疗老年晚期食管癌的疗效和安全性。方法回顾性分析2018年10月—2020年8月安徽省立医院62例行一线化疗的晚期食管癌患者的临床资料。依据治疗方案的不同分为A组(30例)和B组(32例)。A组患者接受卡瑞利珠单抗(200 mg d1)+白蛋白紫杉醇(0.1 g d1、d5)+奈达铂(70 mg/m^(2) d2)/顺铂方案(30 mg d1~d4);B组患者接受白蛋白紫杉醇+奈达铂/顺铂方案。比较两组近期疗效、肿瘤标志物[癌胚抗原(CEA)、鳞状细胞癌抗原(SCC)]水平、毒副反应事件发生率及预后生存情况。结果A组客观缓解率高于B组(P<0.05);两组治疗前后CEA、SCC差值比较,差异有统计学意义(P<0.05),A组治疗前后CEA、SCC的差值高于B组;两组治疗期间腹泻、胃肠道反应、骨髓抑制、肝肾功能损伤总发生率比较,差异无统计学意义(P>0.05);A组存活率高于B组(P<0.05)。结论老年晚期食管癌患者采用卡瑞利珠单抗+白蛋白紫杉醇+奈达铂/顺铂治疗可提高临床疗效,降低肿瘤标志物水平,提高患者近期生存率,且安全性良好。Objective To investigate the efficacy and safety of camrelizumab combined with albumin paclitaxel and nedaplatin/cisplatin in the treatment of elderly patients with advanced esophageal cancer.Methods The clinical data of 62 patients with advanced esophageal squamous cell carcinoma who received first-line chemotherapy in Anhui Provincial Hospital Group from October 2018 to August 2020 were retrospectively analyzed.Thirty patients received camrelizumab(200 mg d1)+nab-paclitaxel(0.1 d1,d5)+nedaplatin(70 mg/m^(2) d2)/cisplatin(30 mg d1 to 4),and 32 patients in group B received nab-paclitaxel+nedaplatin/cisplatin regimen.The short-term efficacy,tumor marker levels[carcinoembryonic antigen(CEA),squamous cell carcinoma antigen(SCC)],incidence of toxic and side effects,and prognosis and survival,were compared between the two groups.Results The objective remission rate of group A was higher than that of group B(P<0.05).Compared with before treatment,the levels of CEA and SCC decreased after treatment(P<0.05).After treatment,CEA and SCC in group A were lower than those in group B(P<0.05).There was no significant difference in the total incidences of diarrhea,gastrointestinal reactions,bone marrow suppression,and liver and kidney function damage between group A and group B during treatment(P>0.05).The survival rate of patients in group A was higher than that in group B(P<0.05).Conclusion The first-line treatment of camrelizumab combined with albumin paclitaxel and nedaplatin/cisplatin in elderly patients with advanced esophageal cancer can improve the clinical efficacy,reduce the level of tumor markers,and prolong the short-term survival rate of patients with good safety.

关 键 词：食管癌 老年 卡瑞利珠单抗 安全性 化学治疗 

分 类 号：R735.1[医药卫生—肿瘤] R979.1[医药卫生—临床医学]